BioLife Solutions BLFS 深 沪
已收盘 08-07 16:00:00 美东时间
34.66
+0.730
+2.15%
华盛通- 最 高34.7614
- 今 开34.27
- 成交量 65.59万股
- 最 低 34.12
- 昨 收 33.93
- 总市值 16.93亿
- 52周最高 34.7614
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 17.86
- 委 比 21.51%
- 总股本 4885.74万
- 历史最高 60.669
- 量 比 1.09
- 振 幅 1.89%
- 历史最低 0.02
- 每 手 1
- 风险率 3.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioLife Details Strategic Repligen Merger Communication to Staff
BioLife Solutions ( ($BLFS) ) has provided an update. On July 21, 2026, BioLife...
08-04 06:21
Repligen soars 16% after blockbuster earnings, FY25 guidance upgrade
Repligen (RGEN) shares rose as much as 16% during Tuesday’s trading following blockbuster second-quarter results and an upward revision to its full-year guidance. RGEN shares advanced 15.91% to $151.9...
07-29 02:49
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion. Repligen Expands Into Cell Therapy The acquisition aims to capitalize on the rapidly expanding...
07-22 21:41
BioLife Solutions To Be Acquired By Repligen For $31 Per Share In Cash And RGEN Stock At EV Of ~$1.5B
BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share. This represents an implied premium of 24% to 90-day volume-weighted average price (VWAP) for the period ended July 21, 2026. Repligen Corporation...
07-22 18:03
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Repligen to acquire BioLife Solutions for $1.5 billion, combining their expertise in cell therapy tools and technologies. The deal includes $11.25 cash and 0.1442 Repligen shares per BioLife share, valued at $31.00. The transaction is expected to boost Repligen's revenue, margins, and EPS by at least $0.05 in year one and $0.25 in year two. Repligen reported 12-13% Q2 revenue growth, while BioLife saw 21% growth year-over-year. The merger is expe...
07-22 10:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares moved upwards by 138.8% t...
03-31 20:05
BioLife Solutions Earnings Report: Q4 Overview
BioLife Solutions (NASDAQ:BLFS) released its Q4 earnings on Thursday, February ...
02-27 05:19
